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Novel TNF receptor-1 inhibitors identified
as potential therapeutic candidates for
traumatic brain injury
Rachel K. Rowe1,2,3*, Jordan L. Harrison4, Hongtao Zhang5, Adam D. Bachstetter6, David P. Hesson5,
Bruce F. O’Hara7, Mark I. Greene5 and Jonathan Lifshitz1,2,3,4
Abstract
Background: Traumatic brain injury (TBI) begins with the application of mechanical force to the head or brain,
which initiates systemic and cellular processes that are hallmarks of the disease. The pathological cascade of secondary
injury processes, including inflammation, can exacerbate brain injury-induced morbidities and thus represents a plausible
target for pharmaceutical therapies. We have pioneered research on post-traumatic sleep, identifying that injury-induced
sleep lasting for 6 h in brain-injured mice coincides with increased cortical levels of inflammatory cytokines, including
tumor necrosis factor (TNF). Here, we apply post-traumatic sleep as a physiological bio-indicator of inflammation. We
hypothesized the efficacy of novel TNF receptor (TNF-R) inhibitors could be screened using post-traumatic sleep and
that these novel compounds would improve functional recovery following diffuse TBI in the mouse.
Methods: Three inhibitors of TNF-R activation were synthesized based on the structure of previously reported TNF
CIAM inhibitor F002, which lodges into a defined TNFR1 cavity at the TNF-binding interface, and screened for in vitro
efficacy of TNF pathway inhibition (IκB phosphorylation). Compounds were screened for in vivo efficacy in modulating
post-traumatic sleep. Compounds were then tested for efficacy in improving functional recovery and verification of
cellular mechanism.
Results: Brain-injured mice treated with Compound 7 (C7) or SGT11 slept significantly less than those treated with
vehicle, suggesting a therapeutic potential to target neuroinflammation. SGT11 restored cognitive, sensorimotor, and
neurological function. C7 and SGT11 significantly decreased cortical inflammatory cytokines 3 h post-TBI.
Conclusions: Using sleep as a bio-indicator of TNF-R-dependent neuroinflammation, we identified C7 and SGT11 as
potential therapeutic candidates for TBI.
Keywords: Diffuse brain injury, Midline fluid percussion, Mouse, Concussion, Cytokines, Tumor necrosis factor
Background
There are approximately 1.7 million TBIs in the USA
annually, with approximately 1.36 million that seek med-
ical treatments [1]. The primary injury caused by a TBI
occurs at the time of the mechanical impact, with lim-
ited possibilities to mitigate this damage; however, sec-
ondary injury processes, such as inflammation, oxidative
stress, and excitotoxicity, amplify the primary damage
and represent plausible targets for pharmaceutical inter-
vention [2]. The development of an effective pharmaco-
logical therapy for acute TBI could prevent, restrict, or
reverse the emergence of chronic post-traumatic mor-
bidities. Such therapy may also require a systematic
pre-clinical paradigm to translate pharmacological neu-
roprotection into improving neurological performance,
as proposed by Janowitz and Menon [3].
Following TBI, the pathophysiological inflammation as
part of secondary injury processes can contribute to
worsening outcome [4, 5], particularly with unregulated
inflammatory cytokine signaling [4–6]. Tumor necrosis
factor (TNF)-α has central nervous system function by
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contributing to the activation of microglia and astrocytes
and release of inflammation mediating cytokines and
can influence blood-brain barrier permeability and syn-
aptic plasticity [7]. TNF functions through interaction
with two members of the TNF-receptor (TNFR) family,
TNFR1 and TNFR2. TNFR1 has been associated with in-
flammation and degeneration, whereas TNFR2 has been
identified as neuroprotective [8, 9], for review see [10].
For this reason, we chose to spare the effects of TNF
through TNFR2 signaling and selectively inhibit TNF
function through TNFR1.
In vitro studies have revealed complex and divergent
TNFR signaling pathways that account for TNF’s ability
to induce cell death, co-stimulation, and cell activation
[11]. TNFR signaling results in the phosphorylation and
degradation of the inhibitor of NF-ĸB (IĸB), which al-
lows for the translocation of NF-ĸB to the nucleus where
it binds DNA and functions as a transcription factor
[11]. Thus, TNF-induced NF-ĸB is a master regulator of
inflammation since NFĸB is a global activator of
pro-inflammatory cytokines, chemokines, and their re-
ceptors [11].
TNF-α is pleiotropic in its actions regarding the regu-
lation of inflammation. Relevant to the current study,
substantial evidence also supports the involvement of
TNF-α in the physiological process of sleep [12–16]. An
increase in sleep is temporally associated with the acute
increase in inflammation following TBI [17]. Therefore,
sleep can be used as a sensitive bio-indicator of the abil-
ity of novel TNFR1 inhibitor compounds to modulate
TBI-induced neuroinflammation and behavioral pheno-
types. Herein, we report that the novel allosteric modu-
lators of TNFR1 inhibitors improved functional recovery
following diffuse TBI in the mouse. In addition, we vali-
dated sleep as a bio-indicator of TNFR1-dependent neu-
roinflammation, which could be applied as a minimally
invasive approach to show therapeutic efficacy in future
clinical studies.
Methods
Study design
In a controlled laboratory experiment, this study tested a
refined pre-clinical strategy to identify and confirm the
utility of experimental compounds with therapeutic po-
tential for treating acute TBI pathophysiology. All animal
studies were conducted in accordance with the guide-
lines established by the internal IACUC (Institutional
Animal Care and Use Committee) and the NIH guide-
lines for the care and use of laboratory animals. Studies
are reported following the ARRIVE (Animal Research:
Reporting In Vivo experiments) guidelines [18].
Randomization of animals was achieved by assigning
animals to treatment groups before the initiation of the
study to ensure equal distribution across groups. A
power analysis was performed to calculate group sizes
that enable statistically robust detection of
injury-induced deficits while minimizing the number of
animals needed. This calculation was based on prelimin-
ary data and previously published work from our group.
Data collection stopped at pre-determined final
endpoints based on days post-injury for each animal.
Animals were excluded from the study if post-operative
weight decreased by 15% of pre-surgical weight (n = 3),
or pre-injury baseline rotarod score was not met (n = 5).
All animal behavior was scored by investigators blinded
to the treatment groups and blinded to drug groups.
Data sets were screened using the extreme studentized
deviate method for significant outliers. One significant
outlier treated with C7 was found and excluded from
the cytokine analyses.
Compound design and synthesis
F002 was the first highly active lead in a series of rigid
propeller-like compounds identified from commercial
databases by docking to a cavity-induced allosteric modi-
fier (CIAM) algorithm identified pocket on TNFR1.
Further modeling efforts combined the propeller-like ar-
rangement of the aryl groups with the goal of improved
solubility, using a propane diol backbone. These changes
led to two novel compounds, C7 and SGT11. C7 had a
slightly better SYBYL-X docking score (2.68), but pos-
sessed a higher molecular weight (567.99) and more li-
pophilicity, with a CLogP score of 5.45. Removal of the
benzyl alcohol acetates from C7 yielded the correspond-
ing bis-benzyl alcohol SGT11 with significantly im-
proved SYBYL-X score (6.15), reduced molecular weight,
and a 2-log drop in CLogP. The total calculated surface
area for all of the molecules were similar and ranged
from 75.53 to 87.67, with SGT11 being smallest. The
compounds were synthesized by Shanghai Medicilion
(Shanghai, China).
In vitro screening
NFκB activity reporter gene assay
To study TNFα-mediated NFκB activity, a luciferase re-
porter system was established. The stable cell line
A549-LUC-14 was derived from human A549 cells with
chromosomal integration of a luciferase reporter construct
regulated by six copies of the NFκB response element.
This clonal cell line was obtained by co-transfection of
pNFκB-TA-luc and pFLAG-TNFR1-neo followed by G418
selection at 800 μg/ml. A549-LUC-14 cells were seeded, at
3000 cells per well, in a 96-well flat-bottom cell culture
plate. After incubation at 37 °C for 24 h, cells were chan-
ged into fresh medium with indicated compounds for 1 h
pre-incubation. Then, 50 μl of medium containing TNF-α
or control was added to each well for a 4-h incubation at
37 °C. The final TNF-α was 5 ng/ml. After 4 h, media
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were removed and cells were gently washed twice with
200 μl DPBS. Twenty-five microliters of 1× reporter
lysis buffer was added to each well at room temperature
and incubated for 5 min, followed with incubation at −
80 °C for 1 h. The plate was thawed at room
temperature, and 20 μl of each sample was transferred
into an opaque 96-well plate to measure luminescence
using a Luminoskan Ascent luminometer (Thermo
Labsystems, Franklin, MA).
Western blot
L929 cells were grown on tissue culture plastic in
complete DMEM supplemented with 5% FBS,
non-essential amino acids, and glutamine. To obtain cell
lysates for western blot, cells treated with TNF-α and in-
hibitors were lysed in a RIPA-based buffer consisting of
20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Nonidet P-40, 1% sodium deoxycho-
late, 10 mM NaF, 1 mM sodium orthovanadate, and
Complete Mini Protease Inhibitors (Roche Diagnostics)
on ice for 15 min and lysates were clarified by centrifu-
gation (16,000 × g) for 10 min. Supernatant was used for
western blot analysis after separation by SDS-PAGE and
was subsequently transferred to a nitrocellulose mem-
brane. Membranes were subsequently blocked with 5%
non-fat dry milk in PBS buffer for 1 h at room
temperature. Membranes were then washed and incu-
bated with primary antibodies (Cell Signaling Technol-
ogy, 1:10,000 dilution), followed by the appropriate
HRP-conjugated secondary antibody. The membrane
was then treated with chemiluminescent HRP substrate
(Millipore) and exposed to Hyblot CL autoradiography
film (Denville Scientific Inc.).
Animals
Male C57BL/6 mice (20–24 g) (Harlan Laboratories,
Inc., Indianapolis, IN) were used for all experiments
(n = 103). Mice were housed in a 14-h light/10-h dark
cycle at a constant temperature (23 °C ± 2 °C) with food
and water available ad libitum according to the
Association for Assessment and Accreditation of
Laboratory Animal Care International. All mice used in
this study were singly housed. Mice were acclimated to
their environment following shipment for at least 3 days
prior to any experiments. After surgery, mice were evalu-
ated daily during post-operative care via a physical exam-
ination and documentation of each animal’s condition.
Animal care was approved by the Institutional Animal
Care and Use Committees at the University of Arizona
(Tucson, AZ).
Midline fluid percussion injury (mFPI)
Since human TBI is a markedly heterogeneous disease,
no single animal model of TBI can reproduce the entire
spectrum of clinical TBI features and symptoms. For this
study, we used the midline fluid percussion injury
(mFPI) model for its clinical relevance (for review see
Lifshitz et al.) [19]. mFPI can model diffuse TBI resulting
in acute behavioral deficits and late-onset behavioral
morbidities in the absence of a focal component, gross
histopathology, and cavitation, as seen with controlled
cortical impact (CCI) [19, 20]. In the current study, adult
male mice (2 months of age) were subjected to midline
fluid percussion injury consistent with methods previ-
ously described [17, 21–25]. Group sizes are indicated in
the “Results” section and figure legends for individual
studies. Mice were anesthetized using 5% isoflurane in
100% oxygen for 5 min, and the head of the mouse was
placed in a stereotaxic frame with continuously delivered
isoflurane at 2.5% via nosecone. While anesthetized,
body temperature was maintained using a Deltaphase®
isothermal heating pad (Braintree Scientific Inc., Brain-
tree, MA). A midline incision was made exposing
bregma and lambda, and fascia was removed from the
surface of the skull. A trephine (3 mm outer diameter)
was used for the craniotomy, centered on the sagittal su-
ture between bregma and lambda without disruption of
the dura. An injury cap prepared from the female por-
tion of a Luer-Loc needle hub was fixed over the crani-
otomy using cyanoacrylate gel and methyl-methacrylate
(Hygenic Corp., Akron, OH). The incision was sutured
at the anterior and posterior edges, and topical Lido-
caine ointment was applied. The injury hub was closed
using a Luer-Loc cap, and mice were placed in a heated
recovery cage and monitored until ambulatory before
being returned to their piezoelectric sleep cage.
For injury induction 24 h post-surgery (approximately
11:00), mice were re-anesthetized with 5% isoflurane de-
livered for 5 min. The cap was removed from the injury
hub assembly, and the dura was visually inspected
through the hub to make sure it was intact with no deb-
ris. The hub was then filled with normal saline and at-
tached to an extension tube connected to the male end
of the fluid percussion device (Custom Design and
Fabrication, Virginia Commonwealth University,
Richmond, VA). An injury of moderate severity for our
injury model (1.1–1.2 atm) was administered by releas-
ing the pendulum onto the fluid-filled cylinder.
Sham-injured mice underwent the same procedure
except the pendulum was not released. Mice were moni-
tored for the presence of a forearm fencing response,
and righting reflex times were recorded for the injured
mice as indicators of injury severity [26]. The righting
reflex time is the total time from the initial impact until
the mouse spontaneously rights itself from a supine pos-
ition. The fencing response is a tonic posturing charac-
terized by extension and flexion of opposite arms that
has been validated as an overt indicator of injury severity
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[26]. The injury hub was removed, and the brain was
inspected for uniform herniation and integrity of the
dura. The dura was intact in all mice, so none were ex-
cluded as technical failures. The incision was cleaned
using saline and closed using sutures. Diffuse
brain-injured mice had righting reflex recovery times
greater than 5 min, less than 11 min, and a positive
fencing response. Sham-injured mice recovered a right-
ing reflex within 20 s. After spontaneously righting, mice
were placed in a heated recovery cage and monitored
until ambulatory (approximately 5 to 15 additional min)
before being returned to their individual sleep cage (vide
infra). Adequate measures were taken to minimize pain
or discomfort [27].
Pharmacological treatment
Mice were treated with vehicle (10% DMSO), C7,
SGT-11, or F002. Compounds were administered intra-
peritoneally at (20 mg/kg) or (2 mg/kg) immediately
following injury. In the subsequent functional and histo-
logical studies, compounds (2 mg/kg) were administered
intraperitoneally twice: immediately following the injury
and 24 h post-injury. Dosing was selected with regard to
published studies using F002 in mice [28] and the solu-
bility of the novel compounds. High doses (20 mg/kg)
were maximum solubility, whereas low doses were one
tenth of that dose (2 mg/kg).
Sleep recordings
The non-invasive sleep cage system (Signal Solutions,
Lexington, KY) used in this study consisted of 16 separ-
ate units that simultaneously monitored sleep and wake
states, as previously published [22, 29, 30]. Each cage
unit housed a single mouse inside 18 × 18-cm walled
compartments with attached food and water structures
[29]. The cages had open bottoms resting on polyvinyli-
dine difluoride (PVDF) sensors serving as the cage floor
[29]. The non-invasive high-throughput PVDF sensors
were coupled to an input differential amplifier, and pres-
sure signals were generated and classified by the classi-
fier as motions consistent with either activity related to
wake or inactivity and regular breathing movements as-
sociated with sleep [22, 29]. Briefly, sleep was character-
ized primarily by periodic (3 Hz) and regular amplitude
signals recorded from the PVDF sensors, which is typical
of respiration from a sleeping mouse. In contrast, signals
characteristic of wake were both the absence of charac-
teristic sleep signals and higher amplitude, irregular sig-
nals associated with volitional movements, even during
quiet wake. The piezoelectric signals in 2-s epochs were
classified by a linear discriminant classifier algorithm
based on multiple signal variables to assign a binary
label of “sleep” or “wake” [29]. Mice sleep in a polycyclic
manner (often more than 40 sleep episodes per hour if
short arousals are recorded) [31], and therefore, mouse
sleep was quantified as the minutes spent sleeping per
hour, presented as a percentage for each hour. Data col-
lected from the cage system were binned over specified
time periods (e.g., 1 h) using the average of percent
sleep, as well as binned by length of individual bouts of
sleep. Where applicable, sleep metrics were compared
between 6 h of light and 6 h of dark.
Rotarod
Sensorimotor function was assessed using the Economex
Rotarod system from Columbus Instruments (Columbus,
OH). Mice were acclimated 3 days prior to surgery/in-
jury. The mice were placed on the stationary rod and
allowed to explore for 30 s. Following exploration, the
mice were placed on the rod at a constant speed of 5 rev-
olutions per minute (rpm). If the mouse fell off the rod,
it was placed back on the rod and the timer was
restarted (until the mice could walk 15 s at 5 rpm). Next,
mice were placed on the rod with a rotation of 5 rpm
and an acceleration of 0.2 rpm/s. The trial ended when
the mouse fell off the rod; after two trials, the acclima-
tion period ended. The testing phase occurred over 3
consecutive days prior to surgery/injury (last test before
surgery was recorded as baseline) and 1, 3, 5, and 7 days
post-injury (DPI). For the post-injury testing phase, mice
were placed on the stationary rod and the instrument
was started at 5 rpm with an acceleration of 0.2 rpm/s.
Two trials were run back to back, after which mice were
returned to holding cages. After 10 min, mice performed
a third trial. The times from the best two trials were av-
eraged to generate a latency to fall from the rotating rod
for each mouse.
Neurological severity score (NSS)
Post-traumatic neurological impairments were assessed
at 24 h post-injury using an eight-point NSS paradigm
implemented from those previously used in experimental
models of TBI [32–35]. One point was given for failure
on an individual task, and no points were given if a
mouse completed a task successfully. Mice were ob-
served for hindlimb flexion, startle reflex, and seeking
behavior (presence of these behaviors was considered
successful task completion). Mice traversed in sequence,
3-, 2-, and 1-cm beams. The beams were elevated, and
mice were given 1 min to travel 30 cm on the beams.
The task was scored as a success if the mouse traveled
30 cm with normal forelimb and hindlimb position
(forelimb/hindlimb did not hang from the beam). Mice
were also required to balance on a 0.5-cm beam and a
0.5-cm round rod for 3 s in a stationary position with
front paws between hind paws. Non-parametric data are
presented as a composite score ranging from zero to
eight representing performance on all tasks combined.
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High final NSS scores were indicative of task failures
and interpreted as neurological impairment.
Novel object recognition (NOR)
Cognitive function was tested using the NOR test as
previously published [22, 36, 37]. The test consisted
of three phases: habituation, training, and testing. On
day 6 post-injury, mice were placed in an open field
(21 × 21 × 42 cm) for 1 h of habituation. Mice were re-
moved and two identical objects were placed in opposing
quadrants of the field for the training phase. Mice were
placed in the center of the open field and given 5 min to
explore the objects. Following training, mice were
returned to their individual sleep cages. Testing began 4 h
after training. One familiar object was placed in an
original location, and one novel object was placed in the
opposing quadrant of the open field. Mice were placed
into the center and given 5 min to explore. For testing,
the times spent actively investigating the novel and famil-
iar object were quantified. Investigation of an object in-
cluded sniffing, touching, or climbing onto an object
while the mouse was facing the object. If an animal
climbed onto an object and sniffed into the air, this time
was not calculated into the exploration of the novel object.
Testing data are reported as the percentage of total
investigation time spent with each object and as a
discrimination index (DI) in which DI = (Tnovel−Tfamiliar)/
(Tnovel + Tfamiliar). A discrimination index of zero indicates
no object preference, and positive values show preference
for the novel object.
Tissue preparation for cytokine measurement and
immunofluorescence
At selected time points (3 h or 7 days) post-injury or
sham operation, mice were given an overdose of sodium
pentobarbital (i.p.) and transcardially perfused with 4%
paraformaldehyde after a phosphate-buffered saline
(PBS) flush. For cytokine measurement, brains were dis-
sected on ice and snap frozen in liquid nitrogen and
then stored at − 80 °C until used. For immunofluores-
cence, brains were removed and placed in 4% parafor-
maldehyde overnight. Brains were immersed in serial
dilutions (15 and 30%) of sucrose for 24 h each. The
brains were removed from the 30% sucrose and frozen
at − 20 °C. After freezing, brains were cryosectioned in
the coronal plane at 20 μm, mounted onto glass slides,
and stored at − 80 °C.
Cytokine measurement
The protein levels of a panel of inflammatory cytokines
were measured in the neocortex by Meso Scale Discov-
ery (MSD) multiplex immunoassay (sector imager 2400,
Meso Scale Discovery; Gaithersburg, MD) as previously
described [38]. Brain cortex was homogenized using
high shear homogenizer (Omni TH115), in a 1:10 (w/v)
of ice-cold lysis buffer consisting of PBS containing
1 μg/ml Leupeptin, 1 mM PMSF, and 1 mM EDTA. The
cortical homogenate was centrifuged at 14,000 × g for
20 min at 4 °C in a microcentrifuge. Fifty microliters of
the resulting supernatant was loaded per well of the cus-
tom MSD plate, and cortical cytokine levels were deter-
mined by MSD assay (Mouse Proinflammatory 7-Plex
Ultra-Sensitive (K15012C)). Cytokine levels in the cortex
were normalized to the total amount of protein in the
sample loaded as determined by BCA Protein Assay
(Pierce).
Iba-1 immunofluorescence
Slides were removed from − 80 °C, placed in an oven at
60 °C for approximately 4 h, and then rinsed three times
for 5 min each in PBS. Next, the slides were incubated
in 4% goat serum blocking solution for 1 h. Slides were
incubated with the primary antibody (rabbit anti-ionized
calcium-binding adaptor molecule 1, IBA-1; 1:1000, Item
# 0199-19741, Wako Chemicals, Richmond, VA) and
stored at 4 °C overnight. Slides were rinsed three times in
PBS and the secondary antibody (biotinylated horse
anti-rabbit; 1:250, Vector Laboratories, Burlingame, CA)
was added and slides were incubated on a rocker at room
temperature for 1 h. Slides were washed in PBS three
times for 5 min each, tertiary stain was applied (streptavi-
din Alexa© Fluor 594; 1:1000, Jackson Immunoresearch,
Westgrove, PA), and slides were incubated for 1 h at room
temperature. Lastly, slides were rinsed three times in PBS
and coverslipped with anti-fade medium (Fluoromount G;
Southern Biotech, Birmingham, AL).
Microglial identification and quantification
Stained sections (four sections per animal; n = 8 per
group) were analyzed following Iba-1 staining to deter-
mine the proportion of microglial morphologies
post-injury. The area of interest, the primary somatosen-
sory barrel fields (S1BF), was chosen based on previous
work demonstrating a focus of neuropathology and micro-
glial activation in the S1BF following midline fluid percus-
sion brain injury in the rodent [39–42]. Sections were
screened using a Zeiss (AXIO imager A2) microscope
with an attached digital camera (AxioCam MRc5). Images
were captured with proprietary Zen software (Carl Zeiss,
Germany) at × 20 magnification. The area of interest was
examined in both hemispheres and in two different cor-
onal sections: an anterior section (~Bregma − 1.555 mm)
and a posterior section (~Bregma − 2.255 mm). A total of
four photos per brain (n = 8 animals per group) per area
of interest were analyzed. Photomicrographs were ana-
lyzed using Image J software (National Institutes of
Health, Bethesda, MD). On each photomicrograph,
250,000 pixel2 grid lines were placed and quantification
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was limited to four pre-defined boxes. Microglia within
these boxes were classified by a blinded investigator as
either having ramified (small soma, high defined pro-
cesses) or activated (hypertrophied soma, fewer pro-
cesses) morphologies. A minimum of 50 microglia were
counted per section per region. Sham treatment groups
were combined.
Statistical analysis
Results are shown as mean ± SEM and analyzed using
GraphPad Prism 6, with statistical significance assigned
at the 95% confidence level (α < 0.05), unless otherwise
indicated. For each test, sham animals receiving each
treatment were compared. No differences were detected
between sham groups (treated and vehicle), so shams
were combined from each treatment. Percent sleep and
differences in rotarod performance were analyzed using
a repeated measure two-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons
test. Improvement on the rotarod was analyzed using a
one-way ANOVA with a Sidak’s multiple comparisons
test. Cumulative sleep measured in minutes and cytokine
levels were analyzed with a one-way ANOVA followed
by Tukey’s multiple comparisons test. Non-parametric
Kruskal-Wallis tests implemented in the statistical pro-
gram R [43] were used to investigate if median NSS
scores differed among groups (including shams) across
and within injury-specific time points. If Kruskal-Wallis
tests were significant (p < 0.05), a post hoc Dunn test im-
plemented in the R package DescTools [44] was per-
formed with p values adjusted using a Bonferroni
correction for multiple comparisons to determine which
groups differed. Identical analytical methods were also
used to investigate if median NSS scores differed among
injury-specific time points without considering a group
effect. Proportional differences in microglia were com-
pared using a one-way ANOVA. For all parametric ana-
lyses, the assumption that data were normally
distributed was verified using density and q-q plots and
Shapiro-Wilk’s tests to ensure the validity of the analyt-
ical approaches used. Resulting test values are included
in the figure legends.
Results
Novel TNF-R1 inhibitors demonstrate target engagement
by blocking TNF-R1 signaling pathways
We have previously reported a novel TNFR1 inhibitor,
F002, which is a cavity-induced allosteric modifier (CIAM)
of TNFR1 that inhibits TNF-α binding to TNFR1 and sub-
sequent pathway activation [45]. To extend properties of
F002, two new analogues were rationally designed and
synthesized by Shanghai Medicilon (Shanghai, China).
The two new compounds, called C7 and SGT11, differed
in the R1 position (SGT11, R1 =OH; C7, R1 =OAc;
Fig. 1a) and efficiently inhibited TNF pathway activation
(Fig. 1b, c). CIAM compounds concentration-dependently
inhibited NF-κB activation as demonstrated by the west-
ern blots of IκBα phosphorylation.
Upon binding to TNFRs, TNFα induces inflammation
through the activation of NFκB and p38 MAPK signaling
pathways. The novel CIAM compounds were tested for
Fig. 1 Novel TNF-R1 inhibitors demonstrate target engagement by
blocking TNF-R1 signaling pathways. a Molecular structures of experimental
compounds (C7 and SGT11) differ at R1 (C7 = OAc, SGT11 = OH),
R2 = CF3. b C7 and SGT11 were tested to inhibit the TNFα-induced
luciferase reporter gene expression controlled by NF-κB promoter.
The percentage of inhibition of TNFα-induced reporter gene
expression is shown. c Inhibition of TNF-α-induced phosphorylation
of IκB in murine fibroblast L929 cells. The cells were pretreated with
inhibitors for 1 h and stimulated by human TNFα at 5 ng/ml for 5 min.
Phosphorylation and total protein levels of IκB and p38 were examined
by western blot. The data represent a typical result derived from
several experiments
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activity to inhibit TNFα-induced NF-κB signaling and
p38 MAPK signaling. An NF-κB reporter gene system
was generated in the human A549 cell line by chromo-
somal integration of a luciferase reporter construct
under the transcriptional control of the NF-κB response
element. In this system, TNFα treatment activates
NF-κB and results in luciferase expression. As shown in
Fig. 1b, both C7 and SGT11 inhibited the luciferase ac-
tivity concentration-dependently. However, SGT11,
which had an IC50 of 5.5 μM, showed greater inhibition
than C7, which did not reach 50% inhibition at 50 μM.
These compounds, which were confirmed to inhibit
NF-κB phosphorylation (Fig. 1c), were selected to move
to in vivo testing. At 25 μM, F002 minimally inhibited
the TNF-α-induced phosphorylation of IκBα (p-IκBα). In
contrast, at 25 μM, both C7 and SGT11 limited p-IκBα
phosphorylation (Fig. 1c). None of these inhibitors dis-
played significant activity on TNF-α-induced p38
phosphorylation.
Novel TNF-R1 inhibitors modulated post-traumatic sleep
In a preliminary cohort of mice, two doses of the three
compounds were tested for their efficacy of modulating
post-traumatic sleep, which is proposed to be a physio-
logical bio-indicator of inflammation. As expected, dif-
fuse TBI resulted in a significant increase in the percent
of post-traumatic sleep over the first 6 h post-injury in
vehicle-treated mice compared to uninjured shams [23]
(Fig. 2a, b). While both doses of compound C7 modu-
lated post-traumatic sleep compared to vehicle sleep
profile, there were no significant differences compared
to vehicle-treated brain-injured mice in the percent sleep
during the first 6 h post-injury or the cumulative mi-
nutes slept (Fig. 2c, d). Both doses of compound SGT
modulated the percent of post-traumatic sleep compared
to vehicle-treated brain-injured mice (Fig. 2e). There
was a significant decrease in the cumulative minutes
slept by the SGT-treated brain-injured mice given a high
dose, compared to the mice given a low dose (Fig. 2f ).
Compound F002 did not significantly modulate the per-
cent of post-traumatic sleep, or cumulative minutes
slept, regardless of the dose given (Fig. 2g, h). Uninjured
sham mice showed no significant drug-induced change
in sleep compared to baseline or the vehicle-treated
group (Additional file 1: Figure S1). Using the modula-
tion of post-traumatic sleep as an indicator of efficacy,
compound C7 and SGT, but not F002, were selected for
further study.
Novel TNF-R1 inhibitors improved functional outcome
measures following TBI
To assess sensorimotor function, the rotarod task was
used as previously published [22, 42, 46]. Motor function
was tested as the latency to fall from the rotating rod
out to 7 days post-injury, with significant effects for time
post-injury and between treatment groups (Fig. 3a, b).
By 3 days post-injury (DPI), SGT attenuated motor defi-
cits compared to vehicle treatment (Fig. 3a) and in-
creased latency to fall from the rod (Fig. 3b). Compound
C7 showed no difference from the vehicle treatment
group. Diffuse TBI led to immediate neurological deficits
measured by a modified Neurological Severity Score
(NSS) at 1, 3, and 5 DPI (Fig. 3c, d). At 3 and 5 DPI,
SGT attenuated neurological deficits observed in
vehicle-treated animals, and by 7 DPI, all injured groups
recovered to uninjured sham performance, as expected.
Cognitive function was measured using the novel object
recognition task (Fig. 3e) [42]. SGT improved cognitive
performance to uninjured sham levels, with SGT-treated
brain-injured mice having a discrimination index higher
than uninjured shams, indicating recall of the familiar
object (Fig. 3f ). To extend findings from the preliminary
screening cohort, we measured sleep immediately fol-
lowing injury in the behavior cohort. TBI led to in-
creased sleep during the first light cycle with C7-treated
brain-injured mice sleeping significantly more at 15:00,
and SGT-treated brain-injured mice sleeping signifi-
cantly more at 15:00 and 17:00 (Fig. 3g). TBI did not sig-
nificantly alter sleep during the transition from light to
dark cycle (Fig. 3g, h). Following the light/dark change
(19:00) sham mice, C7-treated, and SGT11-treated mice
had an increase in sleep. Inversely, vehicle-treated mice
had a decrease in sleep (Fig. 3h); however, this was not
statistically significant. There were no alterations in sleep
during the first dark cycle (Fig. 3h) and no changes dur-
ing the transition from dark to light (Fig. 3h). Overall,
SGT-treated brain-injured mice slept more cumulative
minutes than uninjured shams during the light (sleep)
cycle (Fig. 3i), but mice slept similarly during the dark
(wake) cycle (Fig. 3i).
Novel TNF-R1 inhibitors reduce neuroinflammation
following TBI
Diffuse TBI increased inflammatory cytokines in the cor-
tex at 3 h post-injury, and these increases were attenu-
ated by treatment with C7 and SGT to levels that were
not different from uninjured sham (Fig. 4a–d). Overall,
diffuse TBI increased cortical levels of IL-10 and IL-1β
in vehicle-treated brain-injured mice compared to unin-
jured shams (Fig. 4a, b), but not for cortical TNF-α and
CCL2 levels (Fig. 4c, d). With the administration of ei-
ther compound, cytokine levels were reduced to levels
neither significantly elevated from uninjured sham nor
lower than vehicle-treated brain-injured animals. Treat-
ment with TNF-α receptor inhibitors did not prevent
TBI-induced activation of microglia in the somatosen-
sory cortex among brain-injured animals (Fig. 4e–h). All
brain-injured groups demonstrated a reduced proportion
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of ramified microglia compared to uninjured sham mice
at 7 DPI (Fig. 4e, f ). All brain-injured groups demon-
strated a greater proportion of activated microglia than
uninjured sham mice (Fig. 4g, h).
Discussion
Accumulated and published data indicate that inflamma-
tion contributes to secondary damage following TBI and
therefore represents a plausible therapeutic target for
Fig. 2 Screening of novel TNF-R1 inhibitors showed modulated post-traumatic sleep. Compounds were screened at two doses (high dose 20 mg/kg;
low dose 2 mg/kg) for efficacy in modulating post-traumatic sleep compared to vehicle-treated and uninjured sham mice. Compounds were administered
immediately following injury or sham procedure. A repeated measure two-way ANOVA was used to analyze main effect of treatment on percent sleep
followed by Sidak’s multiple comparisons test when appropriate. Cumulative minutes slept was analyzed between sham and vehicle-treated using an
un-paired t test, and across treatment groups using a one-way ANOVA followed by Tukey’s multiple comparisons test where appropriate. a, b Vehicle-
treated brain-injured mice had a significant main effect of treatment on percent sleep (F1,11 = 6.835, p= 0.0241) and cumulative minutes spent sleeping
(t11 = 2.614, p= 0.0241) compared to uninjured shams. c, dWhile both high- and low-dose compound C7 modulated post-traumatic sleep, there was no
significant treatment effect between brain-injured mice treated with C7 compared to vehicle on percent sleep (F2,9 = 3.135, p= 0.0926) but there was an
overall effect on cumulative minutes spent sleeping (F3,15 = 3.917, p= 0.0300). e, f There was an overall significant treatment effect between brain-injured
mice treated with SGT compared to vehicle on percent sleep (F2,10 = 5.274, p= 0.0273) and cumulative minutes spent sleeping (F3,16 = 5.641, p= 0.0078). g,
h Compound F002 did not significantly modulate percent sleep (F2,10 = 0.2786, p= 0.7625) or cumulative minutes spent sleeping (F3,16 = 2.252, p= 0.1217).
Sleep groups; sham n= 7, vehicle-treated n= 6, C7-low n= 2, C7-high n= 4, SGT-low n= 4, SGT-high n= 3, F002-low n= 4, F002-low n= 3
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Fig. 3 Novel TNF-R1 inhibitors modulated post-traumatic sleep and improved functional outcome measures following TBI. Following preliminary sleep
screening, a second cohort of mice was tested for functional outcome following administration of low-dose (2 mg/kg) compounds given immediately
following injury or sham procedure. a The rotarod was used to test motor function. There was a significant effect of time after injury (F3,102 = 9.612,
p< 0.0001) and group effect on the latency to fall from the rotarod (F3,34 = 6.646, p= 0.0012). SGT attenuated motor deficits by 3 days post-injury (DPI). b
There was a significant time effect (F1,34 = 17.14, p= 0.0002) and treatment effect (F3,34 = 8.450, p= 0.0002). Sidak’s post hoc analysis indicated SGT led to a
significant improvement at 7 DPI compared to 1 DPI. c Neurological deficits were measured by a modified Neurological Severity Score (NSS). Median NSS
scores differed among groups with a treatment effect (χ23 = 32.669; p< 0.001) and time effect (χ
2
3 = 10.178; p= 0.021). At 3 and 5 DPI, SGT attenuated
neurological deficits. d All injured groups showed improvement on the NSS task by 7 DPI. e Cognitive impairment was measured by novel object
recognition (NOR). Differences in time spent exploring the novel versus familiar object revealed a significant difference between investigation times among
sham (t11 = 2.686, p= 0.0212) and SGT-treated brain-injured mice (t9 = 2.277, p= 0.0488), indicating recall of the familiar object. Vehicle-treated brain-injured
mice (t6 = 1.371, p= 0.2195) and C7 treated brain-injured mice (t8 = 1.259, p= 0.2435) spent similar times investigating both objects. f There were no
significant differences in discrimination indices between groups (F3,34 = 0.2276, p= 0.8766). g TBI led to increased sleep during the first light cycle
(F3,25) = 3.933, p= 0.0199). h TBI did not alter sleep during the transition from light to dark cycle (F3,25 = 0.5272, p= 0.6677). i There was an overall effect on
cumulative sleep during the light cycle (F3,25) = 3.233, p= 0.0393) mice slept similarly during the dark cycle (F3,25 = 0.8089, p= 0.5009). Behavior groups:
sham n= 12, vehicle-treated n= 7, C7-treated n= 9, SGT-treated n= 10. Sleep groups: sham n= 9, vehicle-treated n= 5, C7-treated n= 6, SGT-treated n= 9
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Fig. 4 Novel TNF-R1 inhibitors reduce neuroinflammation following TBI. a Vehicle-treated mice, but not C7-treated or SGT-treated brain-injured
mice, had significantly increased IL-10 (F3,19 = 3.217, p = 0.0460) and b IL-1β (F3,19 = 3.831, p = 0.0266) compared to uninjured shams at 3 h post-injury.
c There was an injury-induced increase in TNF-α (F3,19 = 1.977, p = 0.1516) and d CCL2 (F3,19 = 2.340, p = 0.1057) but these increases failed to reach
statistical significance. e, f Iba-1 immunohistochemistry revealed diffuse TBI significantly reduced ramified microglia in the cortex regardless of drug
treatment (F3,26 = 33.57, p < 0.0001). Representative ramified microglia indicated by arrows. g, h All brain-injured groups had a significant increase in
activated microglia compared to uninjured shams (F3,26 = 33.57, p < 0.0001). Representative activated microglia indicated by arrows. Cytokine groups:
sham n = 9, vehicle-treated n = 5, C7-treated n = 4, SGT-treated n = 5. Immunohistochemistry groups: sham n = 7, vehicle-treated n = 7, C7-treated
n = 8, SGT-treated n = 8; scale bar is 20 μm
Rowe et al. Journal of Neuroinflammation  (2018) 15:154 Page 10 of 14
intervention. Universally across rodent models, TNF-α
levels (systemic and central) increase within hours of in-
jury and return to basal levels as early as 24 h
post-injury [24, 46]. TNF-α is an inflammatory cytokine
that stimulates monocyte and glial activation and infil-
tration, neuronal and myelin loss, and blood-brain bar-
rier permeability [47, 48]. TNFR-induced NF-ĸB
activation can transcriptionally induce TNF and thus,
amplify TNF and TNFR signaling pathways, including
the expression of over 20 different cytokines and chemo-
kines and receptors involved in immune regulation [49].
TNF-α binding to the TNF receptor can be blocked
pharmacologically and thereby inhibit subsequent activa-
tion of downstream inflammatory signaling pathways. In
the current study, three compounds (C7, SGT11, and
F002) were synthesized to act as cavity-induced allosteric
modifiers, binding to the TNF receptor and preventing
downstream signaling. Since neuroinflammation and
TNF signaling are pathophysiological hallmarks of clin-
ical TBI [50], these studies set the stage for a pharmaco-
logical pipeline based on therapeutic biomarkers.
The use of sleep as a bio-indicator of inflammation is
a novel approach to screen potential therapeutics. In the
current study, we employ sleep as a valid indicator of in-
flammation. We have previously reported that acute
sleep increases following experimental diffuse TBI and
this increase is temporally associated with increased
cytokine levels [17]. The current findings show diffuse
TBI increased cumulative sleep, which was attenuated
by C7 and SGT11. Furthermore, we were able to investi-
gate two doses of each compound on their efficacy to
modulate a physiological bio-indicator, sleep. We also
showed diffuse TBI increased cortical cytokine levels,
which was attenuated by C7 and SGT11. These data
support the use of sleep as a bio-indicator of acute in-
flammation for screening potential therapeutic com-
pounds, particularly anti-inflammatory compounds.
The novel TNFR1 inhibitors modulated inflammation
via the TNFR1 signaling pathway, as predicted from mo-
lecular modeling. In vivo, compounds with efficacy to
modulate post-traumatic sleep showed efficacy towards
improved motor function following diffuse TBI. Our
data are in line with pre-clinical studies using etanercept
(Enbrel®), a biopharmaceutical marketed to treat auto-
immune diseases by acting as a TNF inhibitor. Rats sys-
temically injected with etanercept and subjected to fluid
percussion brain injury demonstrated reduced motor
and neurological deficits by 3 days post-injury, which
was attributed to the attenuation of microglia activation
and TNF production in the cortex, white matter, hippo-
campus, and hypothalamus [51]. A similar study using a
weight-drop injury model indicated a single systemic in-
jection of TNF-α synthesis inhibitor 3,6′-dithiothalido-
mide (DT) prevented injury-induced increases in TNF-α
and ameliorated neuronal loss and cognitive impair-
ments in the mouse [52]. DT injected in rats for 14 con-
secutive days has also been shown to reverse cognitive
deficits induced by chronic inflammation [53]. A com-
prehensive review of studies using selective TNF inhibi-
tors to treat brain injury and stroke has been previously
published, for review see Tuttolomondo et al. [7].
TNF-α has pleiotropic actions in the brain. TNF-α can
regulate host response to disease, control chemotaxis
through the production of chemokines, regulate monocyte
adhesion molecules, and contribute to microglia activation
[7, 47]. As a potent pro-inflammatory cytokine, TNF
promotes inflammatory signaling and injury-mediated
microglial activation in the central nervous system [6]. In
the current study, TNFR1 inhibiting compounds were
used to prevent TNFR-induced NF-ĸB activation and the
subsequent inflammatory surge [49], as demonstrated in
vitro. We show a decrease in inflammatory cytokines in
the cortex measured at 3 h post-injury, without a change
in microglia activation between vehicle-treated
brain-injured mice and brain-injured mice treated with C7
or SGT. We found C7 and SGT did not reduce microglia
activation at 3 h post-injury in the cortex, possibly indicat-
ing that TNF inhibition was too transient to affect mor-
phological inhibition of microglial activation, despite an
impact on functional outcomes. Extended dosing strat-
egies can test whether these novel compounds can modu-
late microglial activation. Although all measured cytokines
and chemokines in the current study were reduced 3 h
post-injury in brain-injured mice treated with C7 or
SGT11 compared to vehicle, the decrease in TNF-α levels
in the cortex did not reach significance. TNF-α stimulates
the NF-ĸB signaling pathway directly, which can amplify
inflammation and TNF production [49]. It is possible that
TNF produced in response to TBI then induced NF-ĸB
activation, leading to TNF transcription, thereby amplify-
ing TNF and TNFR signaling pathways; these compounds
would not necessarily inhibit TNF-induced TNF amplifi-
cation, even though downstream inflammatory signals
were dampened [11]. This positive auto-regulatory loop
may overall affect TNF levels in the brain while other
pro-inflammatory cytokines attenuate by the inhibition of
TNFR-induced NF-ĸB activation.
Limitations of this study identified by the data require
further support for (i) the role of sleep as predictive
biomarker of underlying inflammation in the brain and (ii)
the therapeutic efficacy of the candidate compounds. First,
cumulative sleep was increased in SGT-treated
brain-injured mice compared to uninjured shams across
the 6-h light cycle immediately following injury, but at 3 h
post-injury, we observed an attenuation of IL-1β, a sleep
regulatory substance, in SGT-treated brain-injured mice.
Also, the uninjured shams had a higher percent sleep than
previously published from our lab [17], which may have
Rowe et al. Journal of Neuroinflammation  (2018) 15:154 Page 11 of 14
reduced power to detect differences among groups. In the
current study, the DMSO vehicle itself could have contrib-
uted to changes in sleep architecture [54]. Cavas et al. re-
ported an increase in sleep following 15 and 20% DMSO
(in saline) administration to rats [54]. Although the
current study used 10% DMSO in saline as a solvent, this
concentration may produce physiological alterations in
sleep architecture in mice, and further investigation into
the effects of DMSO on sleep in the mouse is necessary.
We also note that TNF itself is a modulator of sleep. The
combined sham group for this study included those
treated with vehicle, C7, or SGT11, since sleep was not
significantly different among groups. The experimental
compounds could affect sleep architecture independent of
injury-induced inflammation. To control for this, we ana-
lyzed the change in sleep after compound administration
compared to baseline and the change from vehicle-treated
sham cumulative minutes of sleep (Additional file 1:
Figure S1). All three sham groups slept less in the
post-surgery period compared to the baseline period, but
this change was not dependent on the compound.
Handling of the animals and surgical anesthesia likely con-
tributed to the mice spending more time awake during
the initial hours upon being returned to their cage.
Although targeting TNF in the absence of TBI might in-
fluence sleep, uninjured sham mouse sleep was unaffected
by the experimental compounds.
Further, the route and timing of administration re-
quires further exploration to investigate clinical efficacy.
We also acknowledge that the high dose contributed to
the greatest modulation of post-traumatic sleep; how-
ever, availability and cost of the high dose warranted this
exploratory study with low dose. Lastly, the increase in
sleep could possibly be a result of decreased
wakefulness. Orexin, a pleiotropic neuropeptide, is pro-
duced by neurons in the lateral hypothalamus and gov-
erns survival behaviors, including sleep/wake cycles,
through the promotion of wakefulness [55]. A reduction
in orexin-producing neurons could contribute to a re-
duction in wakefulness observed as an increase in sleep.
Although we do not anticipate a loss in orexin neurons
acutely at 6 h post-injury, further experiments are likely
necessary to investigate brain injury-induced death of
orexin neurons. To increase the efficiency of the pro-
posed systematic pre-clinical approach, flow cytometry
could report on microglial phenotypes in response to
drug treatment as an alternate outcome measure. Using
flow cytometry to quantify cells may prove advantageous
over immunohistochemistry and cell count analyses.
Conclusions
These findings are consistent with improved functional
outcome from brain injury by inhibiting TNFR-induced
NF-ĸB signaling [7, 51–53, 56–59]. In concordance with
previous reports, our results show an accelerated improve-
ment in sensorimotor, neurological, and cognitive function
when brain-injured mice are treated with compounds that
inhibit TNFR1 (Fig. 5). On the basis of these observations,
we add evidence that pharmacological inhibition of
TNF-α is a plausible treatment for acute diffuse brain in-
jury [56]. Furthermore, our results raise the consideration
that post-traumatic sleep can be used as a bio-indicator of
neuroinflammation and operate as a therapeutic bio-
marker; therefore, sleep could serve as a predictive bio-
marker of therapeutic efficacy. We posit that sleep should
be considered as a valuable screening tool for the develop-
ment and testing of drugs that target brain injury-induced
inflammation in the laboratory and possibly the clinic.
Fig. 5 TNF-R1 inhibitors identified as potential therapeutic candidates for diffuse traumatic brain injury. a TNF binds the extracellular domain of
TNF-R1 which leads to TNF-induced activation of NF-κB following the phosphorylation ubiquitination and degradation of inhibitor of κB (IκB)
proteins, thus retaining NF-κB within the cytoplasm. NF-κB activation signals inflammatory pathways leading to an increase in cytokines and
sleep, and a decrease in functional outcome. b Experimental cavity-induced allosteric modifiers (CIAMs) of TNF-R1 bind to the receptor and
prevent TNF from binding. This prevents TNF-induced activation of NF-κB which dampens downstream inflammatory signaling reducing cytokine
production, preventing inflammation-induced sleep, and improving functional outcome
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Additional file
Additional file 1: Figure S1. Uninjured sham mice showed no significant
drug-induced change in sleep compared to baseline or the vehicle treated
group. (A) There was no significant treatment effect on sleep in uninjured
sham mice when compared to their pre-treatment baseline sleep
(F2,6 = 0.6759, p = 0.5436). (B) The change in cumulative sleep from vehicle-
treated shams was calculated and there was no significant treatment effect
on sleep in the C7-treated or SGT-treated shams (t4 = 1.689, p = 0.1665).
(TIF 152 kb)
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